about us

press release






FDA Updates

Clinical Trials

Medical Device News


Aristea Therapeutics Announces Key Leadership Appointments

James M. Mackay, Ph.D., President and CEO of Aristea, commented, "Ciara and Fabio are invaluable members of our Board and management teams, respectively. Both scientists, collectively bring decades of experience in our industry to the company.

Paul Chu, MBA, Appointed VP of Business Development at Phanes Therapeutics

Chu held senior leadership roles in both small biotech companies and large multi-national corporations and has closed deals valued at over $6 billion with a portfolio that spans across oncology, eyecare, neuroscience, and medical aesthetics.

Donald D’Ambrosio Appointed Vivera CFO

Donald D'Ambrosio joins Vivera as a seasoned financial leader. He was nominated twice by the Orange County Business Journal as "CFO of the Year" for his work at MYnd Analytics, where he led the Company's public raise and completed the MYnd uplisting to the Nasdaq Exchange.

Amador Bioscience Appoints New Chief Technology Officer

"Amador is building an industry-leading CRO with advanced technologies and comprehensive capabilities. I'm excited to be a part of it," says Dr Liang. "My entire career has been focusing on applying cutting edge technologies to solve complex problems in pharmaceutical development, and that's what Amador does every day.

John Varian Joins Acorda Therapeutics Board of Directors

John Kelley, Acorda’s Board Chair, added: “I welcome John, on behalf of Acorda’s Board. John has extensive experience as a biopharma leader, including as both a CFO and CEO.

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

"Since I came back to China in 2007, China's biopharmaceutical industry has undergone a momentus shift, from biosimilar-focused into one that nurtures innovation, and from domestic-focused into one that pivots towards globalization," said Dr. Yeh.

Curis Adds Three New Executives to Management Team

James Dentzer, President and CEO: "We are pleased to welcome Felix, Kim and Dora to our management team. They are outstanding professionals in the industry and bring expertise that we believe will strengthen our internal capabilities as we look to advance the development of our clinical drug candidates, CA-4948 and CI-8993.

Biocom California Purchasing Group Appoints Greg Giandomenico as Vice President and Managing Director

“Greg’s strong track record of delivering results in a very competitive space complements Biocom California’s mission of accelerating life science success,” said Rick Fultz, senior vice president and chief business officer of Biocom California.

Eric Dutang Appointed as CFO at biolog-id

“I’m very excited to welcome Eric Dutang to the biolog-id team. His deep-business background, especially in publicly traded companies, is a great addition to our organization,” says Troy Hilsenroth, CEO at biolog-id.